

AUTHOR INDEX
Volume 33
January-June 1986

- Abbate, R., 39
Abdullah, K.A., 357
Aedo, A.-R., 473, 567
Aguilera, E., 203
Allonen, H., 139
Alvarez, F., 111
Amy, J.-J., 529
Annus, J., 69
Anthony, F.W., 463
Apró, G., 69
Assandri, A., 263
Assenzo, J.R., 203
Ayeni, O., 159
Back, D.J., 23, 51, 373, 379
Bader, M., 195
Baird, D.T., 121
Barnea, E.R., 533
Barone, D., 263
Bartfal, G., 69
Beksac, M.S., 327
Belsey, E., 69
Bhattacharyya, A.K., 31
Birgersson, L., 401
Bosch, A.M.G., 591
Bounds, W., 539
Brache, V., 111
Brenner, P.F., 455
Bruni, V., 39
Bucciantini, S., 39
Bulpitt, C., 69
Byers, G., 395
Cagen, R., 487
Cameron, I.T., 121
Cammu, H., 529
Cekan, S.Z., 327, 473
Chadwick, D., 23
Chakravarti, R.N., 245
Chalapati, S., 159
Chandra, H., 47
Chen, Q., 1
Chi, I.-C., 179
Chiang, B.N., 301
Chompootawee, S., 437
Cleveland, P., 23
Colombo, G., 263
Conz, A., 263
Costanzo, G., 39
Costanzo, M., 39
Coulter, A., 127
Cowie, A., 23, 51
Crawford, M.A., 159
Crawford, P., 23
Croxatto, H.B., 347
Deber, R.B., 215
DeCherney, A.H., 533
Dennis, K.J., 463
Devroey, P., 529
Dhall, G.I., 245
Diao, X.-H., 1
Díaz, S., 347
Díaz-Sánchez, V., 579
Diczfalusy, E., 7, 327, 473, 567
Drury, P.J., 159
Dusitsin, N., 159
Edgren, R.A., 547
El-Raghy, I., 373, 379
El Sokkary, H., 365
Ellis, D.J., 547
Eneroth, P., 497
Fakih, M.H., 533
Fan, H.-M., 443
Fathalla, M., 373, 379
Faundes, A., 111
Ferguson, D., 215
Ferla, P., 61
Free, M.J., 285
Galliani, G., 263
Gao, J., 443
Garza-Flores, J., 579
Gellen, J.J., 159
Gilmora, I., 51
Gleicher, N., 423
Goh, T.H., 411
Gomaa, A.A., 357
Grimmer, S.F.M., 51
Guillebaud, J., 539
Gupta, A.N., 245
Han, L.-H., 443
Hasenack, H.G., 591
Hassan, M., 365
Haukkamaa, M., 139, 559
Heng, S.H., 385
Herreros, C., 347
Hicks, J.J., 597
Hong, C.Y., 301
Hoskins, D.D., 605
Huang, J.J., 301
Huber, M., 195
Hutchings, J., 285
Ide, P., 149

CONTRACEPTION

- Indian Council of Medical
Research Task Force on
Hormonal Contraception, 233
Jänne, J., 519
Johannisson, E., 567
Johansson, E.D.B., 347, 401
Käär, K., 591
Kamel, M., 365
Kaminski, J., 1
Klimkow, N.M., 605
Kovacs, L., 69
Krauer, F., 195
Krusius, T., 519
Kubba, A.A., 539
Kushinsky, S., 547
Lähteenmäki, P., 139
Lancini, G.C.263
Landgren, B.-M., 327, 473, 567
Lee, G.J.-L., 547
Lenihan, T., 159
Liew, D.F.M., 385
Lippes, J., 179
Lloyd, T., 395
Lubis, F., 285
Luerti, M., 61
Lukkainen, T., 139
Luz de la Cruz, D., 579
Luzzani, F., 263
Madhavan Nair, K., 307
Majumdar, S., 245
Makeram, M., 379
Mandal, A., 31
Mao, E.T., 195
Mapa, M.K., 245
Masironi, B., 327
McPherson, K., 127
Mears, B.J., 215
Méndez, J.D., 597
Mishell, D.R., Jr., 455
Mistrello, L., 263
Molla, R., 61
Mroszczak, E., 547
Narsinga Rao, B.S., 307
Natakusumah, R., 285
Ng, C.S.A., 385
Nilsson, C.G., 139
Odland, V., 257, 357, 401
Olmsted, A., 547
Olsson, S.-E., 257
Ölund, A., 189
Orme, M.L'E., 23, 51, 373, 379
Oropeza, G., 579
Osman, F., 373, 379
Pavez, M., 347
Perez-Palacios, G., 579
Pinol, A., 69, 159
Pinto, S., 39
Powell, M>G>, 215
Prasad, R.S., 79, 89
Prema, K., 307
Puranen, J., 519
Qian, S.-Z., 105
Ratnam, S.S., 385
Recio, R., 579
Reinprayoon, D., 437
Reyes, A., 579
Rosati, D., 39
Rowlands, S., 539
Salem, H., 379
Salem, H.T., 357
Santini, F., 61
Saperstein, S., 547
Sas, M., 159
Schiavon, R., 579
Schmidt, N.A., 503
Shaaban, M.M., 357
Shen, H., 443
Shi, S., 327
Shoupe, D., 455
Siemens, A.J., 179
Sinervirta, R., 519
Sivakumar, B., 307
Somell, C., 189
Souka, A.R., 365
Spitz, I.M., 455
Stephens, D.T., 605
Stumpf, P.G., 395
Tamsen, L., 497
Taylor, D.R., 463
Tejada, A.S., 111
Temmerman, M., 529
Thijssen, J.H.H., 503
Tjia, J., 23, 51
Toivonen, J., 139
Tong, S.L., 411
Tonta, A., 61
Trienekens, P.H., 503
Tunkeyoon, M., 159
Valles, V., 579
Vermesh, M., 423
Verni, A., 39
Vessey, M., 127

CONTRACEPTION

Vijayan, E., 79, 89
Waller, D.P., 1
Wang, E., 327
Wei, Y.H., 301
Whaley, K.J., 605
Wichmann, K., 519
Wilkins, L.R., 179
Wong, C., 597
Wu, M.-H., 443
Wynants, P., 149
Xu, Y., 105

Yáñez, R., 597
Yao, G.-Z., 443
Yarkoni, S., 533
Zacharias, S., 203
Zalányi, S., Jr., 567
Zanartu, J., 203
Zaneveld, L.J.D., 1
Zbella, E.A., 423
Zheng, S., 443
Zhong, C.-Q., 105

SUBJECT INDEX
VOLUME 33
January - June 1986

- A23187, effect on sperm motility, 301
- Abortifacient effect, Epostane®, 401
- Accessory reproductive organ weights, effect of DL 111-IT (rat),
79
- Actual use data on oral contraceptives, compared with self-
reported histories, 127
- Acute toxicity,
 agent 741 (mouse), 1
 nonoxynol-9 (mouse), 1
- Age, effect on andrological assays, 503
- Agent 741 (alkylphenoxy polyethoxy ethanol(10))
- Alkylphenoxy polyethoxy ethanol(10) (agent 741), spermicidal
 activity and acute toxicity, 1
- Alza T IPCS 52, clinical trial, 437
- 2-Amine-5-iodoacetamide valeric acid,
 effect in endometrium (rat), 597
 effect on embryonic development (rat), 597
 effect on uterine arginase activity (rat), 597
- Andrological assays, effect of age, weight-related parameters and
 hormonal contraceptives, 503
- Androstenedione level, effect of hormonal contraceptives, 503
- Anticonvulsant use,
 effect on ethinyloestradiol + levonorgestrel, 23
 effect on metabolism of levonorgestrel, 257, 559
- Antifertility effect, GTW (rat), 105
- Antiliquefying agents for vaginal contraception, 31
- Antischistosomal drugs, effect on ethinyloestradiol +
 levonorgestrel, 373
- Arginase activity, effect on embryonic development (rat), 597
- Barrier contraceptive, cervical cap, 215, 487
- Bioavailability, ethinyloestradiol + levonorgestrel in patients
 with ileostomy, 51
- Bioavailability of levonorgestrel, intravaginal rings containing
 estradiol + levonorgestrel, 307
- Biochemical studies on conceptus product, effect of DL 111-IT
 (rat, hamster), 263
- Bioequivalence study, different weight tablets and solution of
 ethinyl estradiol + norethindrone, 547
- Biotransformation, desogestrel into 3-keto-desogestrel, 591
- Birth control used and prescribed by physicians, evaluation of
 potential bias, 423
- Bleeding pattern,
 associated with method failure in Norplant® implant users,
 347
 effect of estradiol + levonorgestrel, 307
 effect of estradiol enanthate + dihydroxyprogesterone
 acetophenide, 579
 effect of levonorgestrel, 473
 use of levonorgestrel, 233

CONTRACEPTION

- Blood pressure,
 - effect of ethinylloestradiol + levonorgestrel, 69
 - effect of ethinylloestradiol + norethisterone acetate, 69
- Body weight,
 - effect of DL 111-IT (rat), 79
 - effect of GTW (rat), 105
- Breakage of condoms during use, relationship to laboratory-assessed burst strength, 285
- Breastfed infants, levonorgestrel level when nursing mothers use Norplant® implants, 357
- Burst strength distribution data, monitoring quality of condom stocks, 285
- Carbamazepine treatment, effect on metabolism of levonorgestrel, 559
- Cardiovascular disease, association with oral contraceptives, 7
- Cervical cap, study of safety and effectiveness, 487
- Cervical cap contraception, effectiveness, safety, continuity of use and user satisfaction, 215
- Cervical dilatation for first trimester abortion,
 - use of 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 189
 - use of Gemeprost, 195
 - use of PGF_{2α} gel, 195
- m-Chlorocarbonyl cyanide phenylhydrazone, effect on sperm motility, 301
- Clinical trial, Norplant® and Norplant®-2 contraceptive implants, 233
- Clogestone® acetate (pregna-4,6-diene-20-one-6-chloro-3,17-dihydroxy diacetate)
- Clonazepam treatment, effect on metabolism of levonorgestrel, 559
- Coagulation functions, effect of ethinyl estradiol + levonorgestrel, 39
- Conceptus development, effect of DL 111-IT (rat, hamster), 263
- Condom Deterioration Index, 285
- Condom strength relationship to breakage under use conditions, 285
- Condoms, assessment of burst strength for monitoring quality, 285
- Continuity of use, cervical cap, 215
- Contraceptive practices of female physicians, 423
- Contraceptational action of DL 111-IT (rat, hamster), 263
- Controlled release form of 16,16-dimethyl-trans-Δ₂-PGE₁ methyl ester, use in termination of early pregnancy, 121
- Copper IUD, use as post-coital contraception, 61
- Copper release rate, comparison of ML Cu250, TCu-220C and Cu7 IUDs, 411
- Copper T 220C, clinical trial, 437
- Cortisol level,
 - effect of Epostane®, 401
 - effect of RU 486, 455
- Cu7, pattern of copper loss, 411
- Danazol, use as post-coital contraception, 539
- Day 1 and day 5 "starters", effect of ethinyl oestradiol + levonorgestrel on ovarian function, 463
- Dehydroepiandrosterone-sulfate level, effect of age, weight-related parameters and hormonal contraceptives, 503

- 9-Deoxo-16,16-dimethyl-9-methylene PGE₂, vaginal suppository for cervical dilatation in first trimester abortion, 189
- Depot-medroxyprogesterone acetate,
effect on lactation and incidence of pregnancy, 203
effect on milk lipid and its fatty acid content, 159
metabolic effects, 385
- Desogestrel and 3-keto-desogestrel administration, effect on serum level of 3-keto-desogestrel, 591
- α -Difluoromethylornithine,
effect in endometrium (rat), 597
effect on uterine arginase activity (rat), 597
- 16-16-Dimethyl-trans- Δ_2 -PGE₁ methyl ester, controlled release preparation for early abortion, 121
- Discontinuation rate,
Alza T IPCS 52, 437
copper T 220 C, 437
ethinylloestradiol + levonorgestrel, 69
ethinylloestradiol + norethisterone acetate, 69
Steel Ring, 443
TCu220c, 443
use of levonorgestrel, 233
VCu200, 443
- DL 111-IT (3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1H-1,4-triazole)
- DL 111-IT and hormonal treatment,
effect on testes weight (rat), 89
effect on testicular hyaluronidase activity (rat), 89
- Ectopic pregnancy, use of IUD, 7
- Effectiveness, cervical cap, 215
- Embryonic development,
effect of 2-amine-5-iodoacetamide valeric acid (rat), 597
effect of uterine arginase (rat), 597
- Endocrine profile, long-term Norplant[®] use, 111
- Endometrial morphology,
effect of ethinyl estradiol + desogestrel, 149
effect of ethinyl estradiol + levonorgestrel, 149
effect of medroxyprogesterone acetate, 567
- Endometrium, effect of ethinyl oestradiol + levonorgestrel, 365
- Epileptic patients on anticonvulsant treatment, contraception by Norplant[®] subdermal implants, 559
- Epostane[®] (4,5-epoxy-17-hydroxy-4,17 α -dimethyl-3-oxo-5-androstane, 2-carbonitrile)
abortifacient effects, 401
effect on progesterone synthesis in early pregnancy, 401
- Estradiol + levonorgestrel, bioavailability of levonorgestrel from intravaginal rings, 307
- Estradiol enanthate + dihydroxyprogesterone acetophenide, pharmacodynamic assessment, 579

CONTRACEPTION

- Estradiol level,
 - effect of Epostane®, 401
 - effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 579
 - effect of ethinyl oestradiol + levonorgestrel, 463
 - effect of levonorgestrel, 111
 - effect of medroxyprogesterone acetate, 567
 - measured in urine to assess prediction of ovulation, 327
- Estriol-16-glucuronide level, measured in urine to assess prediction of ovulation, 327
- Estrone-3-glucuronide level, measured in urine to assess prediction of ovulation, 327
- Ethinyl estradiol, radioimmunological assay, 547
- Ethinyl estradiol + desogestrel, effect on endometrial morphology, 149
- Ethinyl estradiol + norethindrone, bioequivalence of different weight tablets and solution, 547
- Ethinyl estradiol + norgestrel, metabolic effects, 385
- Ethinylestradiol + dl-norgestrel, use as post-coital contraception, 61, 539
- Ethinyl estradiol level, administration of ethinyl estradiol + norethindrone, 547
- Ethinylloestradiol + desogestrel, serum level of 3-keto-desogestrel, 591
- Ethinylloestradiol + 3-keto-desogestrel, serum level of 3-keto-desogestrel, 591
- Ethinylloestradiol + levonorgestrel,
 - bioavailability in patients with ileostomy, 51
 - effect of antischistosomal drugs on contraceptive steroid concentrations, 373
 - effect of sodium valproate on pharmacokinetics, 23
 - effect of vaginal administration on ovulation, 365
 - effect on blood pressure, 69
 - effect on endometrial morphology, 149
 - effect on milk lipid and its fatty acid content, 159
 - effect on ovarian function in day 1 and day 5 "starters", 463
 - effect on platelet and coagulation functions, 39
 - pharmacokinetics, 379
 - use as post-coital contraception, 61
- Ethinylloestradiol + norethisterone, pharmacokinetics, 379
- Ethinylloestradiol + norethisterone acetate, effect on blood pressure, 69
- Ethinylloestradiol level,
 - effect of metrifonate, 373
 - effect of praziquantel, 373
 - effect of sodium valproate, 23
 - women with ileostomy, 51
- 3-(2-Ethylphenyl)-5-(3-methoxyphenyl)-1H-1,2,4-triazole (DL 111-IT),
 - effect on testicular hyaluronidase activity (rat), 89
 - effects on testes and accessory reproductive organs (rat), 79
 - mode of action of contragestational agent (rat, hamster), 263

- Expulsion, levonorgestrel-releasing subdermal implants, 233
- Expulsion rate,
 - Steel Ring, 443
 - TCu220c, 443
 - VCu200, 443
- Fallopian tubes, pathological changes following different occlusive techniques (monkey), 245
- Fat in milk, influence of steroidal contraceptives, 159
- Fatty acids in milk samples, influence of steroidal contraceptives, 159
- Female physicians, contraceptive practices, 423
- Fertility, effect of GTW (rat), 105
- Fertility regulation, choice of various methods in India, Indonesia, China and USA, 7
- Filshie's Clip Mark IV, pathological changes in fallopian tubes following tubal occlusion (monkey), 245
- First treatment cycle, effect of ethinyl oestradiol + levonorgestrel in day 1 and day 5 "starters", 463
- FSH (follicle stimulating hormone)
- FSH level,
 - effect of DL 111-IT (rat), 263
 - effect of levonorgestrel, 111
- Gemeprost (PGE₁ analogue), vaginal tablet for cervical dilatation in first trimester abortion, 195
- Gestational age, real time ultrasonography vs pelvic examination, 533
- Glucose level,
 - effect of depot-medroxyprogesterone acetate, 385
 - effect of ethinyl estradiol + norgestrel, 385
- Gossypol, lactate dehydrogenase-C₄ (monkey) as model for understanding mechanism of action, 605
- Gossypol acetate, effect on spermatozoal metabolism, 519
- Gossypol analogues, effect on lactate dehydrogenase-C₄ (monkey) activity, 605
- Gossypol hexamethyl ether, effect on spermatozoal metabolism, 159
- Gossypol tetramethyl ether, effect on spermatozoal metabolism, 519
- GTW (*Tripterigium wilfordii* Hook. f.)
- High density lipoprotein-cholesterol level, effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 579
- Histological studies, effect of GTW (rat), 105
- History of oral contraceptive use, ability of women to recall, 127
- Human chorionic gonadotropin level,
 - during IUD use, 497
 - effect of post-coital contraceptive agents, 539
- Human seminal antiliquefying agents, 31
- Hyaluronidase activity, effect of DL 111-IT on testes (rat), 89
- 17 β -Hydroxy-11 β ,4-dimethyl-aminophenyl-17 β -propynyl estra-4,9-dien-3-one (RU486),
 - determination of antiglucocorticoid effect, 455
 - effect on terminating early pregnancy, 455

CONTRACEPTION

- Ileostomy patients, bioavailability of ethinylloestradiol + levonorgestrel, 51
- Injectable contraceptive,
a review of new developments, 7
depot-medroxyprogesterone acetate, 7, 159, 203, 385
estradiol enanthate + dihydroxyprogesterone acetophenide, 579
norethisterone enanthate, 7
- Insulin level,
effect of depot-medroxyprogesterone acetate, 385
effect of ethinyl estradiol + norgestrel, 385
- Intracervical device, a review of new developments, 7
- Intraoperative ultrasonography, value in first trimester pregnancy terminations, 533
- Intrauterine device (IUD),
a review of new developments, 7
Alza T IPCS 52, 437
copper T, 61
copper T 200, 497
copper T 220 C, 437
copper-releasing, 7
Cu7, 61, 411
levonorgestrel-releasing, 7, 139
Lippes Loop D, 179, 497
MLCu 250, 61, 411
Nova T, 139
progesterone-releasing, 7, 437
risk of ectopic pregnancy, 7
risk of pelvic inflammatory disease, 7
Steel Ring, 443
T-Cu, 203
TCu-220C, 411, 443
VCu200, 443
- Intrauterine pathology, use of ultrasonography, 533
- Intravaginal ring, releasing estradiol + levonorgestrel, 307
- Ionophores, effect on sperm motility, 301
- IUD (intrauterine device)
- IUD insertion,
syncope and other vasovagal reactions, 179
use as post-coital contraception, 61
- IUD use, serum levels of pregnancy-specific β_1 -glycoprotein and human chorionic gonadotropin, 497
- 3-Keto-desogestrel, radioimmunoassay, 591
- 3-Keto-desogestrel level, following administration of desogestrel + ethinylloestradiol and 3-keto-desogestrel + ethinylloestradiol, 591
- Lactate dehydrogenase- C_4 activity,
effect of gossypol analogues, 605
effect of (\pm)-gossypol and (+)-gossypol, 605
- Lactate dehydrogenase- C_4 (monkey) as model for interaction of enzymes with gossypol, 605
- Lactating women, use of levonorgestrel, 357
- Lactation and incidence of pregnancy, effect of hormonal and nonhormonal contraceptives, 203

- Levonorgestrel,
 - bleeding pattern, outcome of pregnancies and levonorgestrel levels associated with method failures, 347
 - clinical trial, 233
 - effect in epileptic patients on anticonvulsant treatment, 559
 - endocrine profile during long-term use, 111
 - pharmacokinetic studies, 473
 - pharmacokinetics in users of intravaginal rings containing estradiol + levonorgestrel, 307
 - release rates from intravaginal rings containing estradiol + levonorgestrel, 307
- Levonorgestrel level,
 - associated with method failure in Norplant implant users, 347
 - effect of anticonvulsant treatment, 559
 - effect of metrifonate, 373
 - effect of phenytoin treatment, 257
 - effect of praziquantel, 373
 - effect of sodium valproate, 23
 - lactating mothers using Norplant® implants and breastfed infants, 357
 - use of intravaginal rings releasing estradiol + levonorgestrel, 307
 - use of levonorgestrel-releasing IUD, 139
 - use of vaginal ring releasing levonorgestrel, 473
 - women with ileostomy, 51
- Levonorgestrel metabolism, effect of phenytoin treatment, 257
- Levonorgestrel-releasing IUD, five years experience, 139
- LH (luteinizing hormone)
- LH level,
 - effect of DL 111-IT (rat), 263
 - effect of ethinyl oestradiol + levonorgestrel, 463
 - effect of levonorgestrel, 111
 - effect of medroxyprogesterone acetate, 567
 - effect of post-coital contraceptive agents, 539
- Lifespan of levonorgestrel-releasing IUD, 139
- Likes and dislikes, use of cervical cap, 215
- Lipids level,
 - effect of depot-medroxyprogesterone acetate, 385
 - effect of ethinyl estradiol + norgestrel, 385
- Lippes Loop D, syncope and other vasovagal reactions at insertion, 179
- Liquefaction time of human seminal coagulum, effect of some compounds, 31
- Madlener's technique, pathological changes in fallopian tubes following tubal occlusion (monkey), 245
- Male antifertility agent, DL 111-IT (rat), 79, 89
- Male antifertility effect, GTW (rat), 105
- Male sterilization, occlusion of vas deferens with methyl cyanoacrylate (monkey), 47
- Mass spectrometry, gossypol ethers, 519
- Medroxyprogesterone acetate, effect on pituitary, ovarian and endometrial function, 567

CONTRACEPTION

- Menstrual cycle,
 effect of estradiol + levonorgestrel, 307
 effect of medroxyprogesterone acetate, 567
 effect of post-coital contraception with danazol, 539
 effect of post-coital contraception with ethinylestradiol
 + dl-norgestrel, 539
- Metabolic effects,
 depot-medroxyprogesterone acetate, 385
 ethinyl estradiol + norgestrel, 385
- Method failure, use of levonorgestrel-releasing subdermal
 implants, 233, 347
- Methyl cyanoacrylate, chemical occlusion of vas deferens
 (monkey), 47
- Metrifonate, effect of ethinylestradiol + levonorgestrel, 373
- Milk lipid and its fatty acid content, influence of steroidal
 contraceptives, 159
- Monensin, effect on sperm motility, 301
- Multiload Cu250 (ML Cu250), pattern of copper loss, 411
- Naphtaldehydes, effect on spermatozoal metabolism, 519
- Neoplasia, risk associated with oral contraceptives, 7
- Nigericin, effect on sperm motility, 301
- Nonactin, effect on sperm motility, 301
- Nonoxynol-9,
 effect on growth of toxic shock syndrome-associated
 Staphylococcus aureus, 395
 spermicidal activity and acute toxicity, 1
- Norethindrone, radioimmunological assay, 547
- Norethindrone level, administration of ethinyl estradiol +
 norethindrone, 547
- dl-Norgestrel, effect on milk lipid and its fatty acid content,
 159
- Norplant® subdermal implants,
 bleeding pattern, outcome of pregnancies and levonorgestrel
 levels associated with method failures, 347
 clinical trial, 233
 effect of phenytoin treatment on metabolism of
 levonorgestrel, 257
 endocrine profile during long-term use, 111
 levonorgestrel concentrations in maternal and infant serum,
 357
 use in epileptic patients on anticonvulsant treatment, 559
- Norplant®-2 subdermal implants, clinical trial, 233
- Nova T, five years experience, 139
- Nucleic acid concentrations, effect of DL 111-IT on testes and
 accessory reproductive organs (rat), 79
- Nucleic acids syntheses in utero-placental complex, effect of
 DL 111-IT (rat, hamster), 263
- Nutritional status, effect on bioavailability of levonorgestrel,
 307
- Occlusion of fallopian tube, pathological changes following
 different techniques (monkey), 245
- Occlusion of vas deferens, use of methyl cyanoacrylate (monkey),
 47
- Oligomycin, effect on sperm motility, 301

- Open-ended vasectomy, clinical evaluation, 529
- Oral contraceptive,
 - Clogestone™ acetate, 203
 - effect on ovulation when administered vaginally, 365
 - ethinyl estradiol + norethindrone, 547
 - ethinyl estradiol + norgestrel, 385
 - ethinylloestradiol + levonorgestrel, 23, 51, 69, 159, 365, 373, 379, 463
 - ethinylloestradiol + norethisterone, 379
 - ethinylloestradiol + norethisterone acetate, 69
 - dl-norgestrel, 159
 - normophasic ethinyl estradiol + desogestrel, 149
 - triphasic ethinyl estradiol + levonorgestrel, 39, 149
- Oral contraceptive histories, ability of women to recall, 127
- Oral contraceptive use, effect on andrological assays, 503
- Oral contraceptives, a review of new developments, 7
- Organ weights, effect of GTW (rat), 105
- Outcome of accidental pregnancies, during Norplant® subdermal implant use, 347
- Ovarian function, effect by ethinyl oestradiol + levonorgestrel in day 1 and day 5 "starters", 463
- Ovulation,
 - effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 579
 - effect of vaginal administration of ethinyl oestradiol + levonorgestrel, 365
 - prediction and/or detection by urinary steroid assays, 327
- Pelvic inflammatory disease, use of IUD, 7
- PG (prostaglandin)
- PGF_{2α} gel, intra-cervical application for cervical dilatation in first trimester abortion, 195
- Pharmacodynamic assessment, estradiol enanthate + dihydroxyprogesterone acetophenide, 579
- Pharmacokinetics,
 - desogestrel, 591
 - ethinylloestradiol, 23, 379, 547
 - 3-keto-desogestrel, 591
 - levonorgestrel, 23, 307, 379, 473
 - medroxyprogesterone acetate, 567
 - norethindrone, 547
 - norethisterone, 379
- Phenytoin + carbamazepine treatment, effect on metabolism of levonorgestrel, 559
- Phenytoin + sodium valproate treatment, effect on metabolism of levonorgestrel, 559
- Phenytoin treatment, effect on metabolism of levonorgestrel, 257, 559
- Platelet, effect of ethinyl estradiol + levonorgestrel, 39
- Polarographic studies, gossypol, gossypol ethers and O-hydroxynaphthaldehyde, 519

CONTRACEPTION

- Post-coital contraception,
 - danazol, 539
 - ethinylestradiol + levonorgestrel, 61
 - ethinylestradiol + dl-norgestrel, 61, 539
 - insertion of copper IUD, 61
- Potential bias of birth control methods prescribed, evaluation of contraceptive practices of female physicians, 423
- Praziquantel, effect on ethinylestradiol + levonorgestrel, 373
- Pregna-4,6-diene-20-one-6-chloro-3,17-dihydroxy diacetate (Clogestone[®] acetate), effect on lactation and incidence of pregnancy, 203
- Pregnancy incidence and lactation, effect of hormonal and non-hormonal contraceptives, 203
- Pregnancy outcome, during Norplant[®] subdermal implants use, 347
- Pregnancy rate,
 - Alza T IPCS 52, 437
 - copper T 220 C, 437
 - Steel Ring, 443
 - TCu220c, 443
 - use of cervical cap, 487
 - use of levonorgestrel, 347
 - VCu200, 443
- Pregnancy-specific β_1 -glycoprotein level, during IUD use, 497
- Pregnanediol-3-glucuronide level,
 - effect of post-coital contraceptive agents, 539
 - measured in urine to assess prediction of ovulation, 327
- Problems,
 - associated with cervical cap use, 215
 - minor and terminal, use of cervical cap, 487
- Progesterone level,
 - effect of Epostane[®], 401
 - effect of estradiol + levonorgestrel, 307
 - effect of estradiol enanthate + dihydroxyprogesterone acetophenide, 579
 - effect of ethinyl oestradiol + levonorgestrel, 365, 463
 - effect of levonorgestrel, 111
 - effect of medroxyprogesterone acetate, 567
 - measured in urine to assess prediction of ovulation, 327
- Prolactin level, effect of DL 111-IT (rat), 263
- Prostaglandin,
 - 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 189
 - 16,16-dimethyl-trans- Δ_2 -PGE₁ methyl ester, 121
 - Gemeprost, PGE₁ analogue, 195
 - PGF_{2 α} gel, 195
- Protein concentration, effect of DL 111-IT on testes and accessory reproductive organs (rat), 79
- Protein syntheses in utero-placental complex, effect of DL 111-IT (rat, hamster), 263
- Real time ultrasonography, value in first trimester pregnancy terminations, 533
- Recall of oral contraceptives histories, accuracy of ability of women, 127
- Release rates of copper, from ML Cu250, TCu-220C and Cu7 IUDs, 411

- Release rates of levonorgestrel, intravaginal rings containing estradiol + levonorgestrel, 307
- RU 486 (17 β -hydroxy-11 β , 4-dimethyl-aminophenyl-17 β -propynyl estra-4,9-dien-3-one)
- Safety, use of cervical cap, 215
- Satisfaction, use of cervical cap, 215
- Self-reported oral contraceptive histories, compared with recorded actual use data, 127
- Seminal antiliquefying agents, 31
- SHBG (sex hormone binding globulin)
- SHBG level,
 - effect of age, weight-related parameters and hormonal contraceptives, 503
 - effect of levonorgestrel, 473
 - effect of phenytoin treatment, 257
- Side effects,
 - post-coital contraception by estrogen/progestogen combination, 61
 - post-coital contraception by IUD insertion, 61
 - use of Epostane[®], 401
 - use of RU 486, 455
 - vaginal administration of ethinyl oestradiol + levonorgestrel, 365
- Sodium valproate, effect on ethinylestradiol + levonorgestrel, 23
- Sperm granuloma, evaluation of open-ended vasectomy, 529
- Sperm motility, effect of some ionophores, 301
- Spermatozoa, effect of GTW (rat), 105
- Spermatozoal metabolism,
 - effect of gossypol acetate, 519
 - effect of gossypol ethers, 519
 - effect of naphthaldehydes, 519
- Spermicidal activity,
 - agent 741 (rabbit, dog, monkey, man), 1
 - nonoxynol-9 (rabbit, dog, monkey, man), 1
- Spontaneous recanalisation, evaluation of open-ended vasectomy, 529
- ST-1435 (16-methylene-17-acetoxy-19-norprogesterone)
- Steel Ring, clinical evaluation, 443
- Subdermal implant contraceptive,
 - a review of new developments, 7
 - levonorgestrel, 7, 111, 233, 257, 347, 357, 559
 - norethisterone, 7
 - progesterone, 7
 - ST-1435, 7
- Syncope and other vasovagal reactions, at insertion of Lippes Loop D, 179
- T-Cu, effect on lactation and incidence of pregnancy, 203
- TCu220C,
 - clinical evaluation, 443
 - pattern of copper loss, 411
- Termination of early pregnancy,
 - use of controlled release form of 16,16-dimethyl-trans- Δ_2 -PGE₁ methyl ester, 121
 - use of RU 486, 455

CONTRACEPTION

- Termination of first trimester pregnancy,
cervical dilatation with 9-deoxo-16,16-dimethyl-9-methylene PGE₂, 189
preoperative cervical dilatation with Gemeprost, 195
preoperative cervical dilatation with PGF_{2α} gel, 195
use of Epostane®, 401
value of real time ultrasonography, 533
- Terminations,
use of cervical cap, 487
use of levonorgestrel-releasing IUD, 139
use of Nova T, 139
- Testes weight,
effect of DL 111-IT (rat), 79, 89
effect of GTW (rat), 105
- Testicular hyaluronidase activity, effect of DL 111-IT (rat), 89
- Testosterone level,
effect of age, weight-related parameters and hormonal contraceptives, 503
effect of GTW (rat), 105
- Toxic shock syndrome-associated Staphylococcus aureus,
effect of nonoxynol-9 on growth, 395
effect of vaginal contraceptive sponges on growth, 395
- Toxicity, effect of GTW (rat), 105
- Tripterigium wilfordii Hook. f. (GTW), effect on fertility (rat), 105
- Tubal ligation, pathological changes in fallopian tubes following different techniques (monkey), 245
- Ultrasonography, value in first trimester pregnancy terminations, 533
- Urinary steroid assays, prediction and/or detection of ovulation, 327
- Utero-placental blood flow, effect of DL 111-IT (rat), 263
- Vacuum aspiration, use of 9-deoxo-16,16-dimethyl-9-methylene PGE₂ vaginal suppository for cervical dilatation, 189
- Vaginal administration of ethinyl oestradiol + levonorgestrel, effect on ovulation, 365
- Vaginal contraceptive sponge, effect on growth of toxic shock syndrome-associated Staphylococcus aureus, 395
- Vaginal ring contraceptive,
a review of new developments, 7
releasing estradiol + levonorgestrel, 7
releasing levonorgestrel, 7, 473
releasing progesterone, 7
- Vas deferens, occlusion with methyl cyanoacrylate (monkey), 47
- Vasectomy, evaluation of open-ended procedure, 529
- Vasovagal reactions, at insertion of Lippes Loop D, 179
- VCu200, clinical evaluation, 443
- Weight-related parameters, effect on andrological assays, 503
- Wood's technique, pathological changes in fallopian tubes following tubal occlusion (monkey), 245

